- Clinical Professor, Global Health
- Clinical Professor, Medicine - Allergy and Infectious Dis.
- CEO, Access to Advanced Health Institute
- Affiliate Professor, Vaccine and Infectious Disease Division, Fred Hutch
Select from the following:
Corey Casper is the President and Chief Executive Officer at the Access to Advanced Health Institute (AAHI), where he oversees the invention, development and manufacturing of technologies for global health including immune-enhancing adjuvant formulations and novel RNA vaccines for infectious disease prevention and cancer immunotherapy.
Dr. Casper received his medical degree from Cornell University, completed an Internal Medicine Residency at UCSF and Infectious Disease Fellowship at the University of Washington (UW), where he also received a Masters of Public Health.
He studies the relationship between infectious diseases, immunity and cancer. He authored >125 peer-reviewed publications, built a comprehensive cancer center in Uganda and the first RNA vaccine manufacturing facilities in Africa (Cape Town). Key scientific contributions include developing clinical diagnostic assays for tumor viruses, completion of Phase 1-3 vaccine trials, and leadership of international immunotherapy licensure trials.
He is a Clinical Professor at UW (Medicine and Global Health) and an Affiliate Professor at the Fred Hutch Cancer Center, where he sees patients with infectious diseases and cancer.
- MD, Cornell University
- MPH, University of Washington
- BA, Wesleyan University
- Biodefense Infectious Diseases
- Cervical Cancer
- Clinical Mentoring
- Drug and Vaccine Development
- Health Disparities
- HIV Transmission
- Infectious Diseases
- Infectious Diseases (other than STDs)
- Innate Immunity
- Laboratory Strengthening
- Leadership and Organizational Development
- Neglected Diseases, Tropical Medicine (incl. Parasites)
- Non-Communicable Diseases
- STDs (other than HIV)
- Waterborne Diseases
- Zoonotic Diseases and Animal Health
- Clinical Development of a Therapeutic Vaccine for Tuberculosis
- Development and Evaluation of a self-amplifying RNA vaccine against the S and N proteins of SARS-CoV-2
- Development and Evaluation of an adjuvanted protein pan-coronavirus vaccine
- Multivalent Flavivirus Vaccine Development Using a Flexible Replicating RNA Platform
Gagliardi A, Porter VL, Zong Z, Bowlby R, Titmuss E, Namirembe C, Griner NB, Petrello H, Bowen J, Chan SK, Culibrk L, Darragh TM, Stoler MH, Wright TC, Gesuwan P, Dyer MA, Ma Y, Mungall KL, Jones SJM, Nakisige C, Novik K, Orem J, Origa M, Gastier-Foster JM, Yarchoan R, Casper C, Mills GB, Rader JS, Ojesina AI, Gerhard DS, Mungall AJ, Marra MA. Analysis of Ugandan cervical carcinomas identifies human papillomavirus clade-specific epigenome and transcriptome landscapes. Nat Genet. 2020;52(8):800-10.
Grande BM, Gerhard DS, Jiang A, Griner NB, Abramson JS, Alexander TB, Allen H, Ayers LW, Bethony JM, Bhatia K, Bowen J, Casper C, Choi JK, Culibrk L, Davidsen TM, Dyer MA, Gastier-Foster JM, Gesuwan P, Greiner TC, Gross TG, Hanf B, Harris NL, He Y, Irvin JD, Jaffe ES, Jones SJM, Kerchan P, Knoetze N, Leal FE, Lichtenberg TM, Ma Y, Martin JP, Martin MR, Mbulaiteye SM, Mullighan CG, Mungall AJ, Namirembe C, Novik K, Noy A, Ogwang MD, Omoding A, Orem J, Reynolds SJ, Rushton CK, Sandlund JT, Schmitz R, Taylor C, Wilson WH, Wright GW, Zhao EY, Marra MA, Morin RD, Staudt LM. Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma. Blood. 2019 Mar 21;133(12):1313-1324. doi: 10.1182/blood-2018-09-871418. Epub 2019 Jan 7. PubMed PMID: 30617194; PubMed Central PMCID: PMC6428665.
Santiago JC, Goldman JD, Zhao H, Pankow AP, Okuku F, Schmitt MW, Chen LH, Hill CA, Casper C, Phipps WT, Mullins JI. Intra-Host Changes in Kaposi Sarcoma-Associated Herpesvirus Genomes in Ugandan Adults with Kaposi Sarcoma. PLoS Pathog 2021; 17 (1): e1008594.
Voigt EA, Gerhardt A, Hanson D, Battisti P, Reed S, Singh J, Mohamath R, Jennewein MF, Bakken J, Beaver S, Press C, Soon-Shiong P, Paddon CJ, Fox CB, Casper C. A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability. NPG Vaccines 2022 (in press)
Duthie MS, Frevol A, Day T, Coler RN, Vergara J, Rolf T, Sagawa ZK, Marie Beckmann A, Casper C, Reed SG. A phase 1 antigen dose escalation trial to evaluate safety, tolerability and immunogenicity of the leprosy vaccine candidate LepVax (LEP-F1 + GLA-SE) in healthy adults. Vaccine. 2020;38(7):1700-7. Epub 2020/01/04. doi: 10.1016/j.vaccine.2019.12.050. PubMed PMID: 31899025.